Transgene is a
clinical-stage biotechnology company

focused on designing and developing
novel immunotherapeutics.

Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for patients.

A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer.


Our approach uses the mechanisms of the immune response to enable the patient’s body to fight against disease.







of staff dedicated to R&D

Management committee
and Board of Directors


Management committee

Dr Alessandro RIVA, MD

Chairman and CEO

Dr. Riva has nearly 30 years’ experience in the Life Sciences industry.  He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma.
Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals.
Dr. Riva currently serves on the Boards of BeiGene and Century Therapeutics. He received his bachelor’s degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.


Chairman and Chief Executive Officer (CEO)


Executive Vice President and Vice President, Research & Development

Eric Quéméneur joined Transgene in September 2014 as Executive Vice President in charge of Research and Development. Before joining Transgene, he spent over 20 years at the CEA (Atomic Energy Commission) where he was Director of research programs and industrial partnerships in the life science division. His responsibilities included: the management of R&D programs and their transition into applications, the management of multidisciplinary teams and the development of national and international alliances. Eric Quéméneur has a PhD in Biochemistry from the Claude Bernard University in Lyon, France. He is the author of nearly 80 articles published in international scientific journals.

Executive VP, & Chief Scientific Officer (CSO)
Christophe ANCEL, PharmD

Christophe ANCEL


VP, Pharmaceutical Operations & Qualified Pharmacist

Christophe Ancel joined Transgene in 2008, first as Head of Quality Assurance and then as Vice President, Operational Quality. Prior to that, he was a consultant for several international pharmaceutical groups. From 2001 to 2005, he was Head of Quality, Assistant Pharmacist and Interim Responsible Pharmacist for the French production site of E. Lilly. In 2001, he was Director of Quality Assurance and Interim Responsible Pharmacist for a Cardinal Health site. From 1992 to 2000, he worked on Quality Assurance for Alcon Laboratories and was Assistant Pharmacist at the production site. He has international work experience in the areas of production and commercialization of sterile products. Christophe qualified as a Doctor of Pharmacy.


VP, Pharmaceutical Operations & Qualified Pharmacist


VP Medical Affairs & Chief Medical Officer (CMO) 

Maud Brandely joined Transgene as Chief Medical Officer in March 2016. Maud Brandely was previously Director of Clinical Development at Pierre Fabre Oncologie until February 2016. She was responsible for all clinical trials from Phase I to Phase III. As such, she was involved in the successful registrations of Navelbine oral in breast cancer and NSCLC and vinflunine in transitional cell carcinoma of the urothelial tract. Prior to Pierre Fabre, Maud was Director of Taxotere clinical development at Rhone-Poulenc (RPR, now Sanofi) and was responsible for setting up global registration of clinical studies in both the US and Europe. As such she shared her time between Collegeville and Paris to oversee her US and European teams. Before RPR, she worked at Hoescht-Roussel-Uclaf (now Sanofi) and was involved in the development of cytokines (Il2, IFN) and cytotoxics. Maud is an MD and obtained a PhD in Immunology.

VP Medical Affairs & Chief Medical Officer (CMO)

Lucie Larguier

VP, Chief Financial Officer (CFO)

Since 2016, Lucie has served as Director Corporate Communications and Investor Relations, reporting to the CEO. Specialist in financial communications and press relations, Lucie came with over 10 years’ experience in communications agencies. She spent 3 years as a financial communications consultant at Ogilvy PR (2006 to 2008) before joining Citigate Dewe Rogerson (2009-2016). Her strategic contribution helped to ensure the smooth execution of four successful securities transactions, as well as multiple scientific, clinical and corporate announcements. Within the Paris office, she has also created a franchise dedicated to biotech companies, combining the sector expertise of the London subsidiary with her perfect knowledge of the French financial ecosystem.

Lucie will join Transgene’s Executive Committee in December 2023 as Vice President Corporate Communications and Investor Relations.

She is a graduate of Paris Institute of Political Studies (Sciences Po), with a Master’s degree in communication with a specialization in finance.


Chief Financial Officer (CFO)


VP, General Counsel & Corporate Secretary

John Felitti joined Transgene in March 2016 as General Counsel & Corporate Secretary. Before joining Transgene, he was Associate Vice President, Corporate Law, Finance & Securities Law at Sanofi and previously held other positions in the Sanofi and the Aventis legal departments. From 1996 to 2003, he was an associate attorney at the Paris offices of the global U.S. law firm Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar. After majoring in economics at Harvard University (AB 1991) and the College of Europe (MA 1993), John Felitti studied law at the University of Michigan (JD 1996) and the University of Paris II – Panthéon (LLM 1997). He also holds a business degree from INSEAD (GEMBA 2015).


VP, General Counsel & Corporate Secretary
Christelle SCHWOERER

Christelle SCHWOERER

VP, Human Resources Director

Christelle SCHWOERER was appointed Director of Human Resources and joined the Executive Committee in April 2024.

She joined Transgene’s Human Resources department in December 2013 as a Human Resources Assistant, after initial experience in construction and industry.

Her various roles at Transgene have enabled her to develop generalist skills in human resources and to contribute to projects of major importance to the company. Her knowledge of the organization, its culture and its employees are real assets in her new missions.

Christelle SCHWOERER holds a Master 1 Ressources Humaines from the CNAM Grand-Est and a Master 2 Management – Ressources Humaines from the Ecole de Management de Strasbourg, obtained in 2020 and 2021.

Human Resources Director
James Wentworth, PhD

VP, Chief Business Officer

James Wentworth, PhD, joined Transgene in 2024. Dr. Wentworth is responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies.

He has over 15 years of experience working in the pharma and biotech industry.  James was Director, Business Development and Strategy at Adaptimmune, a NASDAQ-listed biotechnology company focused on developing T-cell receptor (TCR)-based cell therapies for solid tumors. His responsibilities included strategic pharma partnering, collaborations and transactions, corporate development projects, commercial strategy development and he also led the company’s competitive intelligence function. Prior to Adaptimmune, James worked with precommercial Biotech companies at inVentiv Health (now Syneos Health) and held strategic roles at Shire, contributing to product development, post M&A integration, and managing commercial launches in European markets for ViroPharma Europe.

James holds a BSc Hons degree in Pharmacology and a PhD in Pharmacology both from the University of Bristol and an MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland.


VP, Chief Business Officer



Board of Directors

Dr. Alessandro RIVA, MD

Chairman and CEO

Dr. Riva has nearly 30 years’ experience in the Life Sciences industry.  He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma and led its integration and growth. He also managed the US and EU approvals of Yescarta, the first approved CAR-T cell therapy for adult patients with diffuse large B cell lymphoma.
Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals.
Dr. Riva currently serves on the Boards of BeiGene and Century Therapeutics. He received his bachelor’s degree in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.


Committees: Member of the Strategy Committee and of the Clinical Development Committee

Chairman and CEO



Honorary Chairman

Alain Mérieux is Chairman of Institut Mérieux, a family holding company dedicated to medicine and public health worldwide.

In 1963, Alain Mérieux founded bioMérieux, an in vitro diagnostics company. From 1968 to 1994, he was Chairman of Institut Mérieux, which specialized in human and veterinary vaccines, before divesting the vaccine business. In 1994, he created a new bio-industrial pole in the field of diagnostics (bioMérieux), immunotherapy (Transgene and ABL), food safety and nutrition (Mérieux NutriSciences) and health investments (Mérieux Equity Partners).

He is President of Fondation Mérieux, an independent family foundation recognized as being in the public interest, which fights against infectious diseases in developing countries.

Alain Mérieux holds a PhD in Pharmacy. He served as an interna resident in the hospitals of Lyon and attended the PMD at Harvard Business School


Honorary Chairman




Philippe Archinard, Ph.D. has been Executive Vice-President, Technological Innovation and Scientific Partnerships at Institut Mérieux since 2021. He was Chairman and Chief Executive Officer of Transgene from 2010 to 2020; and CEO from 2004 to 2020. Previously he was CEO of Innogenetics from 2000 to 2010. From 1985 to 2000, he held various positions at bioMérieux, including management of bioMérieux, Inc. in the United States. He is a chemical engineer and has a Ph.D. in biochemistry from the University of Lyon, and supplemented his education with a management program at the Harvard Business School. He is Chairman of the Institut des Recherches Technologiques (IRT) BIOASTER.

Philippe Archinard, Ph.D., has been a Director of the Company since 2004.

Committees: Member of the Strategy Committee and Member of the Clinical Development Committee



Michel Baguenault de Puchesse

Michel Baguenault


Michel Baguenault de Puchesse has been CEO of Institut Mérieux since January 2020. Prior to this position, Michel held several positions within the Institut Mérieux group: Executive Vice President of Institut Mérieux (2009 – 2011), Corporate Vice President, HR and Communication of bioMérieux (2011 – 2016), Secretary General of bioMérieux, in charge of Human Resources, Communication, Audit – Risks & Compliance, and Protocol (2016 – 2020).
Before joining Institut Mérieux, he was Financial Strategy Advisor at Financière Meeschaert, from 1996 to 2004, and Head of Development at Banque Martin Maurel in Lyon, from 2004 to 2008. Michel Baguenault de Puchesse is a graduate from EM LYON Business School and holds a Law degree. Within the Institut Mérieux Group, Michel Baguenault de Puchesse is a board member of Institut Mérieux, Mérieux NutriSciences, Fondation Christophe & Rodolphe Mérieux, and non-executive President of Mérieux Equity Partners.

Outside the Group, he is board member of CIC Lyonnaise de Banque, Descours & Cabaud SA, Mutuelles AXA, Siparex / Sigefi, Fondation Solidarités by Crédit Agricole. He also joined the supervisory board of Unibel.





Director, Chairman of the Strategy Committee

Jean-Luc Bélingard was Chairman and Chief Executive Officer of bioMérieux S.A from 2010 to 2017. He graduated from the Ecole des Hautes Etudes Commerciales (HEC) of Paris (1971) and holds a Master of Business Administration (MBA) from Cornell University, US (1974). Since then, he has held management positions at Merck, Sharp and Dohme (1974-1983), Roche France (“Président du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMérieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010).

Jean-Luc Bélingard has been a Director of the Company since 2013.

Committee: Chairman of the Strategy Committee


Director, Chairman of the Strategy Committee

Prof. Jean-Yves BLAY, MD, PhD

Independent Director, Chairman of the Clinical Development Committee 

Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads the LYriCAN project (integrated cancer research) at the French National Cancer Institute. Former president of the European Organization for Research and Treatment of Cancer, Prof. Jean‑Yves Blay is currently director of the NETSARC network accredited by the French National Cancer Institute and president of the French Sarcoma Group. At international level, he is a faculty member of the ESMO (European Society of Medical Oncology) and the SPH (Scientific Panel for Health).  He has led the European Commission’s Conticanet network and is currently leading the Eurosarc FP7 project. Author of more than 500 international publications, Prof. Jean-Yves Blay advises various national and international research organizations and institutions. His work has been rewarded by several prizes including that of the French National Academy of Medicine, which he joined as a corresponding member in 2014.

Committee: Chairman of the Clinical Development Committee


Independent Director, Chairman of the Clinical Development Committee




Benoît Habert is Executive Vice President and Director of the Marcel Dassault Industrial Group and is a board member of several listed and private companies. He holds an MBA from INSEAD and a Master of Business Law.

Benoît Habert has been a Director of the Company since 2000.

Committees: member of the Compensation Committee and of the Audit Committee





Independent Director, Chairwoman of the Audit Committee

Marie Landel founded Marie Landel & associates, now Axelia Partners, a consultancy based in Cambridge (Massachusetts) specialized in advising European companies on the creation and development of US subsidiaries. She has significant experience supporting French and European biotechnology companies in the United States. With more than 30 years of practice, she has built an extensive network in the financial community focused on this sector. Marie Landel is a French CPA (Expert-comptable), and she holds an MBA from the European Business School (Paris, Frankfurt and London). She also sat on the Boards of TxCell, Safe Orthopaedics and Cellnovo. Chevalier de la Légion d’Honneur et de l’Ordre du Mérite, Marie Landel was also a Foreign Trade Advisor to the French government (CCEF or Conseillers pour le Commerce Extérieur de la France for 10 years). She is now a member of the French Tech Hub in Miami. As a member of Women Initiative Foundation, she coaches Women Entrepreneur.

Marie Landel has been a Director of the Company since 2017.

Committee: Chairwoman of the Audit Committee, member of the ESG Committee


Independent Director, Chairwoman of the Audit Committee

Maya SAID, PhD

Independent Director

Maya Said has been an independent Director of Transgene since 2017. She brings more than 15 years of international experience in the healthcare industry. Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis, and Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D at Sanofi. Her career started within the HealthCare and Strategy practice of The Boston Consulting Group (BCG). Maya has a PhD in Computer Science & Systems Biology from the Massachusetts Institute of Technology (MIT), as well as two Master’s degrees in Electrical Engineering & Computer Science and in Biology. She has also studied finance and healthcare organizational systems at the Harvard Business School. Maya is the author of more than 20 publications in peer-reviewed journals.

Committees: Chairwoman of the Compensation Committee, member of the Strategy Committee and Clinical Development Committee


Independent Director, Chairwoman of the Compensation committee


Independent Director 

Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of directors of Ipsen (where she chaired the audit committee) and Epizyme, Inc. Carol Stuckley was formerly Chief Financial Officer and Senior Vice President at HPS, which was acquired by TransUnion, Inc. Previously, Carol was Chief Financial Officer, Vice President, Finance at Galderma North America (Nestlé Skin Health S.A.). Carol started her 23-year career at Pfizer Inc., where she held multiple financial roles of increasing responsibility, and was most recently Assistant Treasurer, Vice President, Finance and Corporate Officer of Pfizer Inc. A US citizen, Carol holds a Master of Arts Degree in Economics and an MBA in International Finance from Temple University’s Fox Business School.

Committee: Member of the Audit Committee and of the Compensation Committee


Independent Director


Sandrine Flory

Director, represented by Sandrine FLORY

TSGH SAS has been Transgene’s reference shareholder since 1994. This financial holding company is a member of Institut Mérieux Group and is in fine owned by the Mérieux family and by the Christophe and Rodolphe Mérieux Foundation. Philippe Archinard is CEO of TSGH. Sandrine Flory has been TSGH’s permanent representative on Transgene’s Board of Directors since January 2021.

Sandrine Flory has been Chief Financial Officer of Institut Mérieux since 2020. She has spent 18 years at bioMérieux, in various positions in finance. She was CFO for bioMérieux EMEA from 2014 to 2020. Prior to joining bioMérieux, Sandrine Flory spent 9 years at PriceWaterhouseCoopers in France and Australia. She holds a Master’s degree in Finance and Accounting and a MS in Business Valuation and Transmission from the Université Lyon 2 (France).

The financial holding company TSGH has been a Director of the Company since 2002, Sandrine Flory is its representative since 2021.

Committees: Chairwoman of the ESG Committee, member of the Audit Committee


Director, represented by Sandrine FLORY (Chairwoman of the ESG committee)

Last update : June 2023.

Scientific advisors


Scientific advisors

John C. Bell, PhD

Scientific advisor


John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and clinically testing novel immunotherapeutics for the treatment of cancer. He is a co-founder of OV biotechs Jennerex and Turnstone Biologics. John is a senior scientist at the Ottawa Hospital Research Institute (OHRI), a research institution affiliated with the University of Ottawa and the research arm of The Ottawa Hospital. John launched his independent research career in the Department of Biochemistry at McGill University.

His research program has been continuously funded by peer-reviewed grants for over 30 years and he has authored over 400 publications.

He completed his post-doctoral studies at the Medical Research Council in London, England and received his PhD in virology and immunology at McMaster University in Ontario, Canada.




Scientific advisor
Pedro Romero, MD

Scientific advisor 


Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer.

Previously, Pedro researched at the Department of Medical and Molecular Parasitology at New York University School of Medicine before joining the Ludwig Institute for Cancer Research (LICR), Epalinges, Switzerland, in 1989. In 2001, he became division Head of Clinical Onco-Immunology at the LICR in Lausanne.

Pedro holds a number of patents and has coauthored more than 320 original research articles describing his scientific works in peptide-based immunotherapy and T cell responses.

Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.






Scientific advisor

Last update: March 2023.

Corporate governance

Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and accepted by regulators as guidance for best governance practices.


Board of Directors

The Board of Directors is currently composed of ten members, elected for renewable three-year terms. Four members of the Board are independent directors as defined in the Code. The Board is chaired by the Chairman and Chief Executive Officer. The Board has adopted a charter of internal regulations that governs the conduct of the Board of Directors and its committees. Detailed information can be found in the Registration Document.
 Rules of procedure of the Board of Directors

The Board of Directors is assisted by several committees:

The Audit Committee is composed of three directors of the Board, two of whom are independent. The Vice President Finance is invited to attend each Committee meeting to present the financial situation of the Company. The Audit Committee’s operations are governed by a charter that is reviewed regularly. The committee regularly reports on its work and provides recommendations to the Board of Directors.
 Rules of procedure of the audit committee of the Board of Directors

The Compensation Committee is composed of three independent directors two of whom are independent, and is responsible for recommending to the Board of Directors the salaries, bonuses and share-based compensation to executives and key personnel of the Company.
 Rules of procedure of the compensation committee of the Board of Directors

The Environmental Social and Governance (ESG) Committee is composed of three directors, one of whom is independent. It was established by a decision of December 15, 2021. The ESG Committee is responsible for preparing discussions for the Board on issues relating to the Company’s social and environmental responsibility and for making recommendations to the Board of Directors in this area.
 Rules of procedure of the ESG committee of the Board of Directors (in French)

Management Committee

The Management Committee is a non-statutory body that oversees the Company’s daily operations and ensures, in all managerial aspects, that the Company’s strategy is properly executed in accordance with its objectives.

Governance and internal procedures

The Company has established a number of other internal bodies and procedures, for example, for financial controlling, project management and risk management.

 Charter on regulated agreements and the procedure for evaluating ordinary-course agreements (In French)

Ethics & compliance

Transgene, in the conduct of its activities, aims to act with integrity and in full compliance with its regulatory and legal environment.

Transgene has set up a compliance program addressing business ethics, the protection of personal data and including specific tools, such as a whistleblowing system. 

The Internal Audit department of Institut Mérieux, Transgene’s parent company, contributes to the evaluation, continuous improvement, and integrity of Transgene’s compliance program.  




Transgene upholds the highest ethical standards of business integrity, and all our employees, partners and suppliers must observe the highest ethical standards defined by Transgene.

Code of Conduct

Transgene has established a Code of Conduct that all employees, directors, and business partners must observe. The Code of Conduct, sets out the general framework for the professional behavior in relation to customers, suppliers, the export of equipment, financial integrity, conflicts of interest, information technology system, etc.

 Code of Conduct

Anti-Corruption Code

Transgene’s Anti-corruption and influence peddling Code sets out the rules that our employees must respect, in terms of gifts, signs of courtesy, hospitality or specific rules applicable to healthcare professionals, etc.

 Anti-Corruption Code

Supplier Code of Ethics

Transgene attaches great importance to ensuring that its partners share a set of common rules, practices, and principles with respect to business ethics and social responsibility. Therefore, Transgene requires its suppliers to respect the ethical principles presented in the Supplier Code of Ethics which defines principles such as: competitive tendering, equal opportunity in the tendering process, confidentiality, integrity and courtesy.

 Supplier Code of Ethics

Insider Trading Policy applicable to Transgene

As a company listed on the stock market, Transgene has adopted an Insider Trading Policy to specify the rules with which the employees and managers are required to comply to the extent that they may have access to Inside Information concerning Transgene. It aims both to inform about the applicable laws and regulations, and to put in place additional measures to prevent situations that could create the appearance of insider dealing.

 Insider Trading Policy applicable to Transgene (in French)




To ensure personal information is protected, we apply a strict privacy and security policy and raise awareness on this topic among all Transgene’s employees.


Transgene‘s personal data protection policy aims to inform the data subjects (customers, patients, suppliers and partners) what personal information is collected, how it is processed and retained.


 General Privacy and Personal Data Protection policy


Laws and regulations relating to the protection of personal data give the right to individuals (called Data Subjects) to manage the personal data concerning them that has been collected by companies (called Data Controllers) in the course of their activities.


In accordance with applicable rules, the Data Subjects are entitled to exercise the following rights:


  • To be informed of the existence and purpose of all processing of their Personal Data;
  • To access their Personal Data, and to request rectification or deletion of their Personal Data, or the restricting of its processing;
  • To object to the processing as well as to request the portability of Personal Data;
  • To withdraw his/her consent given to Transgene at any time;
  • To rapidly inform the Group manager in charge of data protection of any loss or abuse (illegal processing) of his/her Personal Data.

As Data Controller, Transgene is required to process personal data as part of its activities. As such, Transgene understands the importance of guaranteeing the principles of privacy rights and thus of providing concrete answers and explanations to your requests to exercise your rights.


For any questions regarding Transgene’s Privacy Policy, please contact


In order to exercise your rights, we invite you to complete the following form and send it by email to the address:

or by post to the postal address,for the attention of the Compliance officer, Transgene, Parc d’Innovation, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch Graffenstaden


Rights exercise form




Transgene has a zero-tolerance policy concerning unethical behavior, corrupt practices, influence peddling, fraud, misappropriation, theft, harassment, and discrimination.


If you are a witness or victim of a prejudicial situation, do not hesitate to complete a report via our reporting platform which guarantees the anonymity and confidentiality of the exchanges.


Transgene provides employees and external stakeholders (customers, suppliers or anyone interacting with Transgene) with an alert system to report inappropriate behaviour that is contrary to the law, our values or the principles mentioned in our Code of Conduct and our Anti-corruption and influence peddling Code.

This online alert platform, secure and accessible from any Internet browser, is available continuously (24 hours a day, 7 days a week) at the following address:  


An alert can also be reported by post to the postal address, for the attention of the Compliance Officer, Transgene, Parc d’Innovation, 400 Boulevard Gonthier d’Andernach, 67400 Illkirch Graffenstaden.


To find out more about how the whistleblowing system works, please consult Transgene’s whistleblowing procedure (In French).



We participate in exchanges and collaborations with the aim of developing our R&D expertise, our product portfolio, and our processes. Transgene is engaged in several collaborative programs with public and private partners, in France and worldwide.

Clinical collaboration agreements with:

Alliance of Merck KGaA and Pfizer (TG4001)

MSD (BT-001)

Collaborative research agreements with:

NEC (artificial intelligence for myvac®)

BioInvent (ICI vectorization)

Randox (SdAb vectorization)

Strategic agreement:

Sale of the rights of TG1050 and TG6002 to Tasly Biopharmaceuticals for Greater China

And also…


Transgene is an active member of the following clusters

Reference Clinical Centers

Transgene works closely with many renowned clinical centers in France, Europe and globally such as